Conclusions
RA
REMISSION
In this post hoc evaluation of AVERT-2, among individual patients with early, biomarker-defined RA who achieved clinically stringent endpoints such as SDAI or Boolean remission at IP week 24 with SC abatacept QW + MTX, a high proportion of individual patients (56–58%) sustained their responses through week 52.Furthermore, numerically more patients who achieved early and sustained SDAI remission in the IP maintained remission during the DE period of the study if they continued weekly treatment with abatacept (either in combination with MTX or as monotherapy) than patients who tapered then withdrew abatacept therapy or those who continued treatment with abatacept placebo + MTX. The achievement of early remission or other clinically relevant outcomes by individual patients treated with weekly SC abatacept + MTX may be indicative of sustained efficacy over time.